Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tavolimab |
Synonyms | |
Therapy Description |
Tavolimab (MEDI0562) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 1052PD). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tavolimab | MEDI0562|MEDI-0562|Tavolixizumab | OX40 Antibody 14 | Tavolimab (MEDI0562) is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 1052PD). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03336606 | Phase I | Tavolimab | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | Active, not recruiting | USA | 0 |
NCT02318394 | Phase I | Tavolimab | A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors | Completed | USA | 1 |